The long and winding road towards new treatments against lymphatic filariasis and onchocerciasis.

Autor: Risch F; Institute for Medical Microbiology, Immunology, and Parasitology, University Hospital Bonn, Germany; German Center for Infection Research (DZIF), partner site Bonn-Cologne, Bonn, Germany., Kazakov A; Institute for Medical Microbiology, Immunology, and Parasitology, University Hospital Bonn, Germany; German Center for Infection Research (DZIF), partner site Bonn-Cologne, Bonn, Germany., Specht S; Drugs for Neglected Diseases initiative, Geneva, Switzerland., Pfarr K; Institute for Medical Microbiology, Immunology, and Parasitology, University Hospital Bonn, Germany; German Center for Infection Research (DZIF), partner site Bonn-Cologne, Bonn, Germany., Fischer PU; Division of Infectious Diseases, John T. Milliken Department of Internal Medicine, Washington University School of Medicine, St Louis, MO, USA., Hoerauf A; Institute for Medical Microbiology, Immunology, and Parasitology, University Hospital Bonn, Germany; German Center for Infection Research (DZIF), partner site Bonn-Cologne, Bonn, Germany., Hübner MP; Institute for Medical Microbiology, Immunology, and Parasitology, University Hospital Bonn, Germany; German Center for Infection Research (DZIF), partner site Bonn-Cologne, Bonn, Germany. Electronic address: huebner@uni-bonn.de.
Jazyk: angličtina
Zdroj: Trends in parasitology [Trends Parasitol] 2024 Sep; Vol. 40 (9), pp. 829-845. Date of Electronic Publication: 2024 Aug 08.
DOI: 10.1016/j.pt.2024.07.005
Abstrakt: Although lymphatic filariasis and onchocerciasis have been targeted for global elimination, these helminth infections are still a major public health problem across the tropics and subtropics. Despite decades of research, treatment options remain limited and drugs that completely clear the infections, and can be used on a large scale, are still unavailable. In the present review we discuss the strengths and weaknesses of currently available treatments and new ones in development. Novel candidates (corallopyronin A, DNDi-6166, emodepside, and oxfendazole) are currently moving through (pre)clinical development, while the development of two candidates (AWZ1066S and ABBV-4083/flubentylosin) was recently halted. The preclinical R&D pipeline for filarial infections continues to be limited, and recent setbacks highlight the importance of continuous drug discovery and testing.
Competing Interests: Declaration of interests A.H., K.P., and S.S. hold three patents for corallopyronin A to treat human and animal filarial infections (US 9168244 B2, US 9687470 B2, and EP 2704708 B1). M.P.H., K.P., and A.H. have applied for a patent concerning solid and liquisolid formulations of corallopyronin A (application US20230181522A1). M.H. and A.H. are members of the section antiparasitic therapy of the Paul Ehrlich Gesellschaft für Infektionstherapie and board members of the German Society for Tropical Medicine Travel Medicine and Global Health (DTG). M.H. is also a board member of the German Society of Parasitology (DGP). All other authors declare no competing interests.
(Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: